VEGFA and neoplasm: Although the addition of bevacizumab represents a breakthrough in overcoming VEGF-mediated immunosuppression in the tumor microenvironment (TME)5, further post-hoc analysis has suggested a lack of efficacy for subsets including HCC arising from non-alcoholic steatohepatitis6 or HCC harboring Wnt/beta-catenin mutations7,8.